{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T18:48:34Z","timestamp":1794768514460,"version":"4.9.1"},"reference-count":79,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T00:00:00Z","timestamp":1715126400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.biopha.2024.116737","type":"journal-article","created":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T02:50:30Z","timestamp":1715655030000},"page":"116737","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"C","title":["Efficient systemic CNS delivery of a therapeutic antisense oligonucleotide with a blood-brain barrier-penetrating ApoE-derived peptide"],"prefix":"10.1016","volume":"175","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0052-4213","authenticated-orcid":false,"given":"Yuan Qi","family":"Yeoh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azin","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2442-5000","authenticated-orcid":false,"given":"Brittany","family":"Cuic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7536-7808","authenticated-orcid":false,"given":"Doris","family":"Tomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley J.","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2611-9996","authenticated-orcid":false,"given":"Fazel","family":"Shabanpoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2024.116737_bib1","doi-asserted-by":"crossref","DOI":"10.1212\/NXG.0000000000000323","article-title":"Antisense oligonucleotides","volume":"5","author":"Scoles","year":"2019","journal-title":"Neurol. Genet"},{"key":"10.1016\/j.biopha.2024.116737_bib2","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3390\/cells9010137","article-title":"RNA-based therapeutics: from antisense oligonucleotides to miRNAs","volume":"9","author":"Bajan","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.biopha.2024.116737_bib3","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1146\/annurev-pharmtox-010818-021050","article-title":"Therapeutic oligonucleotides: state of the art","volume":"59","author":"Smith","year":"2019","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.biopha.2024.116737_bib4","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1089\/nat.2022.0054","article-title":"Drug Metabolism and pharmacokinetics of antisense oligonucleotide therapeutics: typical profiles, evaluation approaches, and points to consider compared with small molecule drugs","volume":"33","author":"Takakusa","year":"2023","journal-title":"Nucleic Acid. Ther."},{"key":"10.1016\/j.biopha.2024.116737_bib5","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.4161\/cc.5.18.3192","article-title":"Delivery of RNA interference","volume":"5","author":"Li","year":"2006","journal-title":"Cell Cycle"},{"key":"10.1016\/j.biopha.2024.116737_bib6","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.omtn.2020.10.001","article-title":"Amido-bridged nucleic acid-modified antisense oligonucleotides targeting SYT13 to treat peritoneal metastasis of gastric cancer","volume":"22","author":"Kanda","year":"2020","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.biopha.2024.116737_bib7","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.3390\/ijms22073295","article-title":"Recent advances in oligonucleotide therapeutics in oncology","volume":"22","author":"Xiong","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2024.116737_bib8","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1701329","article-title":"Cardiovascular and metabolic effects of ANGPTL3 antisense oligonucleotides","volume":"377","author":"Graham","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2024.116737_bib9","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s12265-013-9495-7","article-title":"Antisense technology: an emerging platform for cardiovascular disease therapeutics","volume":"6","author":"Lee","year":"2013","journal-title":"J. Cardiovasc Transl."},{"key":"10.1016\/j.biopha.2024.116737_bib10","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1146\/annurev-neuro-070918-050501","article-title":"Antisense oligonucleotide therapies for neurodegenerative diseases","volume":"42","author":"Bennett","year":"2019","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.biopha.2024.116737_bib11","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3390\/pharmaceutics14010200","article-title":"Safe and effective cynomolgus monkey GLP-Tox Study with repetitive intrathecal application of a TGFBR2 Targeting LNA-gapmer antisense oligonucleotide as treatment candidate for neurodegenerative disorders","volume":"14","author":"Peters","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biopha.2024.116737_bib12","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s40265-017-0711-7","article-title":"Nusinersen: first global approval","volume":"77","author":"Hoy","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.biopha.2024.116737_bib13","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1016\/S0140-6736(08)60921-6","article-title":"Spinal muscular atrophy","volume":"371","author":"Lunn","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2024.116737_bib14","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2024.116737_bib15","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.molmed.2012.11.002","article-title":"Spinal muscular atrophy: going beyond the motor neuron","volume":"19","author":"Hamilton","year":"2013","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.biopha.2024.116737_bib16","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1146\/annurev-pharmtox-010919-023738","article-title":"Antisense drugs make sense for neurological diseases","volume":"61","author":"Bennett","year":"2021","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.biopha.2024.116737_bib17","doi-asserted-by":"crossref","DOI":"10.1177\/1756285618754501","article-title":"Advances in spinal muscular atrophy therapeutics","volume":"11","author":"Parente","year":"2018","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.biopha.2024.116737_bib18","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1089\/nat.2017.0665","article-title":"FDA approval of nusinersen for spinal muscular atrophy makes 2016 the year of splice modulating oligonucleotides","volume":"27","author":"Aartsma-Rus","year":"2017","journal-title":"Nucleic Acid. Ther."},{"key":"10.1016\/j.biopha.2024.116737_bib19","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1080\/14737175.2017.1364159","article-title":"Nusinersen for the treatment of spinal muscular atrophy","volume":"17","author":"Chiriboga","year":"2017","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.biopha.2024.116737_bib20","doi-asserted-by":"crossref","unstructured":"S. Bazaz, T. Lehto, R. Tops, O. Gissberg, D. Gupta, B. Bestas, J. Bost, O.P.B. Wiklander, H. Sork, E.M. Zaghloul, D.R. Mamand, M. H\u00e4llbrink, R. Sillard, O. Saher, K. Ezzat, C.I.E. Smith, S.E. Andaloussi, T. LehtoNovel orthogonally hydrocarbon-modified cell-penetrating peptide nanoparticles mediate efficient delivery of splice-switching antisense oligonucleotides in vitro and in\u00a0vivo 9 Biomedicines\u200b , 2021, , 1046.","DOI":"10.3390\/biomedicines9081046"},{"key":"10.1016\/j.biopha.2024.116737_bib21","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.addr.2015.03.008","article-title":"Antisense oligonucleotides in therapy for neurodegenerative disorders","volume":"87","author":"Evers","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.biopha.2024.116737_bib22","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.addr.2015.01.008","article-title":"Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides","volume":"87","author":"Geary","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.biopha.2024.116737_bib23","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.4103\/1673-5374.239435","article-title":"Analysis of the trafficking system in blood-brain barrier models by high content screening microscopy","volume":"13","author":"Toth","year":"2018","journal-title":"Neural Regen. Res."},{"key":"10.1016\/j.biopha.2024.116737_bib24","doi-asserted-by":"crossref","first-page":"545","DOI":"10.15252\/emmm.201607199","article-title":"Delivery is key: lessons learnt from developing splice-switching antisense therapies","volume":"9","author":"Godfrey","year":"2017","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.biopha.2024.116737_bib25","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1021\/jm970538o","article-title":"Synthesis and biodistribution of a short nonionic oligonucleotide analogue in mouse with a potential to mimic peptides","volume":"41","author":"Eschgf\u00e4ller","year":"1998","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biopha.2024.116737_bib26","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S0022-3565(25)39459-0","article-title":"Disposition of the 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats","volume":"267","author":"Cossum","year":"1993","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.biopha.2024.116737_bib27","article-title":"Safety, tolerability, and effect of nusinersen treatment in ambulatory adults with 5q-SMA","volume":"12","author":"Elsheikh","year":"2021","journal-title":"Front. Neurol."},{"key":"10.1016\/j.biopha.2024.116737_bib28","doi-asserted-by":"crossref","first-page":"e413","DOI":"10.1212\/WNL.0000000000009914","article-title":"Nusinersen in adult patients with spinal muscular atrophy: observations from a single center","volume":"95","author":"Moshe-Lilie","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.biopha.2024.116737_bib29","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.1093\/nar\/gkaa299","article-title":"Phosphorothioate modified oligonucleotide\u2013protein interactions","volume":"48","author":"Crooke","year":"2020","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.biopha.2024.116737_bib30","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.3390\/jcm9062004","article-title":"Antisense oligonucleotides: an emerging area in drug discovery and development","volume":"9","author":"Dhuri","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.biopha.2024.116737_bib31","doi-asserted-by":"crossref","first-page":"66","DOI":"10.4161\/15384047.2014.987009","article-title":"Liposome-coated lipoplex\u2013based carrier for antisense oligonucleotides","volume":"16","author":"Wyrozumska","year":"2015","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.biopha.2024.116737_bib32","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1128\/AAC.01542-08","article-title":"Novel anion liposome-encapsulated antisense oligonucleotide restores susceptibility of methicillin-resistant Staphylococcus aureus and rescues mice from lethal sepsis by targeting mecA","volume":"53","author":"Meng","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.biopha.2024.116737_bib33","doi-asserted-by":"crossref","first-page":"8173","DOI":"10.1002\/anie.201914751","article-title":"Systemic brain delivery of antisense oligonucleotides across the blood\u2013brain barrier with a glucose-coated polymeric nanocarrier","volume":"59","author":"Min","year":"2020","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.biopha.2024.116737_bib34","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.21873\/anticanres.13285","article-title":"Delivery of antisense oligonucleotide LOR-2501 using transferrin-conjugated polyethylenimine-based lipid nanoparticle","volume":"39","author":"Zheng","year":"2019","journal-title":"Anticancer Res"},{"key":"10.1016\/j.biopha.2024.116737_bib35","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.omtn.2018.04.004","article-title":"Antibody-antisense oligonucleotide conjugate downregulates a key gene in glioblastoma stem cells","volume":"11","author":"Arnold","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.biopha.2024.116737_bib36","doi-asserted-by":"crossref","first-page":"632","DOI":"10.2119\/molmed.2015.00210","article-title":"Novel targeted therapy for precursor B cell acute lymphoblastic leukemia: anti-CD22 antibody-MXD3 antisense oligonucleotide conjugate","volume":"22","author":"Satake","year":"2016","journal-title":"Mol. Med."},{"key":"10.1016\/j.biopha.2024.116737_bib37","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.154142","article-title":"Antibody-oligonucleotide conjugate achieves CNS delivery in animal models for spinal muscular atrophy","volume":"7","author":"Hammond","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.biopha.2024.116737_bib38","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2012.30","article-title":"Pip6-PMO, a new generation of peptide-oligonucleotide conjugates with improved cardiac exon skipping activity for DMD treatment","volume":"1","author":"Betts","year":"2012","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.biopha.2024.116737_bib39","doi-asserted-by":"crossref","first-page":"10825","DOI":"10.1039\/D0TB01106A","article-title":"Intracellular delivery of therapeutic antisense oligonucleotides targeting mRNA coding mitochondrial proteins by cell-penetrating peptides","volume":"8","author":"Cerrato","year":"2020","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.biopha.2024.116737_bib40","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1089\/nat.2016.0652","article-title":"Identification of a peptide for systemic brain delivery of a morpholino oligonucleotide in mouse models of spinal muscular atrophy","volume":"27","author":"Shabanpoor","year":"2017","journal-title":"Nucleic Acid. Ther."},{"key":"10.1016\/j.biopha.2024.116737_bib41","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1021\/acs.molpharmaceut.0c00160","article-title":"Improved cellular delivery of antisense oligonucleotide for miRNA-21 imaging in vivo using cell-penetrating peptide-based nanoprobes","volume":"18","author":"Yang","year":"2021","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.biopha.2024.116737_bib42","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3389\/fphar.2020.00697","article-title":"Cell-penetrating peptides in diagnosis and treatment of human diseases: from preclinical research to clinical application","volume":"11","author":"Xie","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biopha.2024.116737_bib43","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1021\/ar200256e","article-title":"Efficient intracellular delivery of nucleic acid pharmaceuticals using cell-penetrating peptides","volume":"45","author":"Nakase","year":"2012","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.biopha.2024.116737_bib44","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1021\/acs.molpharmaceut.1c00788","article-title":"Incorporation of endosomolytic peptides with varying disruption mechanisms into EGFR-targeted protein conjugates: the effect on intracellular protein delivery and EGFR specificity in breast cancer cells","volume":"19","author":"Lieser","year":"2022","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.biopha.2024.116737_bib45","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1021\/acs.bioconjchem.8b00799","article-title":"Endosomal escape and cytosolic penetration of macromolecules mediated by synthetic delivery agents","volume":"30","author":"Brock","year":"2019","journal-title":"Bioconjugate Chem."},{"key":"10.1016\/j.biopha.2024.116737_bib46","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jconrel.2010.11.004","article-title":"Endosomal escape pathways for delivery of biologicals","volume":"151","author":"Varkouhi","year":"2011","journal-title":"J. Control. Release"},{"key":"10.1016\/j.biopha.2024.116737_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120398","article-title":"Endosomal escape cell-penetrating peptides significantly enhance pharmacological effectiveness and CNS activity of systemically administered antisense oligonucleotides","volume":"599","author":"Dastpeyman","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.biopha.2024.116737_bib48","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1021\/acs.bioconjchem.8b00908","article-title":"Thiol-cyanobenzothiazole ligation for the efficient preparation of peptide\u2013PNA conjugates","volume":"30","author":"Patil","year":"2019","journal-title":"Bioconjugate Chem."},{"key":"10.1016\/j.biopha.2024.116737_bib49","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.neuint.2017.02.016","article-title":"Combination of valproic acid and morpholino splice-switching oligonucleotide produces improved outcomes in spinal muscular atrophy patient-derived fibroblasts","volume":"108","author":"Farrelly-Rosch","year":"2017","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.biopha.2024.116737_bib50","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1089\/oli.1.1996.6.267","article-title":"Resistance of morpholino phosphorodiamidate oligomers to enzymatic degradation","volume":"6","author":"Hudziak","year":"1996","journal-title":"Antisense Nucleic Acid. Drug Dev."},{"key":"10.1016\/j.biopha.2024.116737_bib51","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1093\/nar\/gkaa126","article-title":"Comparison of the efficacy of MOE and PMO modifications of systemic antisense oligonucleotides in a severe SMA mouse model","volume":"48","author":"Sheng","year":"2020","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.biopha.2024.116737_bib52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/nat.2016.0657","article-title":"FDA approves eteplirsen for duchenne muscular dystrophy: the next chapter in the eteplirsen saga","volume":"27","author":"Aartsma-Rus","year":"2017","journal-title":"Nucleic Acid. Ther."},{"key":"10.1016\/j.biopha.2024.116737_bib53","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1083\/jcb.138.4.877","article-title":"A new function for the LDL receptor: transcytosis of LDL across the blood-brain barrier","volume":"138","author":"Dehouck","year":"1997","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.biopha.2024.116737_bib54","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/312162a0","article-title":"Transferrin receptor on endothelium of brain capillaries","volume":"312","author":"Jefferies","year":"1984","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2024.116737_bib55","doi-asserted-by":"crossref","first-page":"8409","DOI":"10.1039\/C8SC02415D","article-title":"Branched BBB-shuttle peptides: chemoselective modification of proteins to enhance blood\u2013brain barrier transport","volume":"9","author":"D\u00edaz-Perlas","year":"2018","journal-title":"Chem. Sci."},{"key":"10.1016\/j.biopha.2024.116737_bib56","doi-asserted-by":"crossref","first-page":"3967","DOI":"10.1002\/anie.201411408","article-title":"Applying the retro-enantio approach to obtain a peptide capable of overcoming the blood\u2013brain barrier","volume":"54","author":"Prades","year":"2015","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.biopha.2024.116737_bib57","doi-asserted-by":"crossref","first-page":"7194","DOI":"10.1016\/j.biomaterials.2012.06.063","article-title":"Delivery of gold nanoparticles to the brain by conjugation with a peptide that recognizes the transferrin receptor","volume":"33","author":"Prades","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.biopha.2024.116737_bib58","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.3390\/ph5111177","article-title":"Improving the endosomal escape of cell-penetrating peptides and their cargos: strategies and challenges","volume":"5","author":"Erazo-Oliveras","year":"2012","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.biopha.2024.116737_bib59","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-35938-8","article-title":"HAI peptide and backbone analogs\u2014validation and enhancement of biostability and bioactivity of BBB shuttles","volume":"8","author":"Arranz-Gibert","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2024.116737_bib60","doi-asserted-by":"crossref","DOI":"10.2144\/fsoa-2022-0013","article-title":"Optimized peptide extraction method for analysis of antimicrobial peptide Kn2-7\/dKn2-7 stability in human serum by LC-MS","volume":"8","author":"Chen","year":"2022","journal-title":"Future Sci. OA"},{"key":"10.1016\/j.biopha.2024.116737_bib61","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1139\/O09-129","article-title":"Membrane catalysis of peptide-receptor binding","volume":"88","author":"Langelaan","year":"2010","journal-title":"Biochem Cell Biol."},{"key":"10.1016\/j.biopha.2024.116737_bib62","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-14784-0","article-title":"Apelin conformational and binding equilibria upon micelle interaction primarily depend on membrane-mimetic headgroup","volume":"7","author":"Shin","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2024.116737_bib63","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3762\/bjnano.11.10","article-title":"Internalization mechanisms of cell-penetrating peptides","volume":"11","author":"Ruseska","year":"2020","journal-title":"Beilstein J. Nanotechnol."},{"key":"10.1016\/j.biopha.2024.116737_bib64","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1111\/bph.12106","article-title":"Exploring avidity: understanding the potential gains in functional affinity and target residence time of bivalent and heterobivalent ligands","volume":"168","author":"Vauquelin","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.biopha.2024.116737_bib65","doi-asserted-by":"crossref","first-page":"10962","DOI":"10.1073\/pnas.1605731113","article-title":"Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophy","volume":"113","author":"Hammond","year":"2016","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.biopha.2024.116737_bib66","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1007\/s11095-021-03118-5","article-title":"Pharmacokinetic\/pharmacodynamic modeling of a cell-penetrating peptide phosphorodiamidate morpholino oligomer in mdx mice","volume":"38","author":"Mukashyaka","year":"2021","journal-title":"Pharm. Res"},{"key":"10.1016\/j.biopha.2024.116737_bib67","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.nmd.2011.09.007","article-title":"A critical smn threshold in mice dictates onset of an intermediate spinal muscular atrophy phenotype associated with a distinct neuromuscular junction pathology","volume":"22","author":"Bowerman","year":"2012","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.biopha.2024.116737_bib68","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.nmd.2023.03.008","article-title":"Safety, tolerability and pharmacokinetics of eteplirsen in young boys aged 6\u201348 months with Duchenne muscular dystrophy amenable to exon 51 skipping","volume":"33","author":"Mercuri","year":"2023","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.biopha.2024.116737_bib69","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19092714","article-title":"Peptides as therapeutic agents for inflammatory-related diseases","volume":"19","author":"La Manna","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2024.116737_bib70","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.764654","article-title":"Heptamethine cyanine\u2013based application for cancer theranostics","volume":"12","author":"Zhang","year":"2022","journal-title":"Front. Pharm."},{"key":"10.1016\/j.biopha.2024.116737_bib71","doi-asserted-by":"crossref","first-page":"344","DOI":"10.3390\/pharmaceutics7030344","article-title":"Enhancement of blood-brain barrier permeability and delivery of antisense oligonucleotides or plasmid DNA to the brain by the combination of bubble liposomes and high-intensity focused ultrasound","volume":"7","author":"Negishi","year":"2015","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biopha.2024.116737_bib72","doi-asserted-by":"crossref","first-page":"7328","DOI":"10.1021\/bi036208p","article-title":"Two apolipoprotein E mimetic peptides, ApoE(130\u2212149) and ApoE(141\u2212155)2","volume":"43","author":"Croy","year":"2004","journal-title":"Bind LRP1, Biochem."},{"key":"10.1016\/j.biopha.2024.116737_bib73","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1021\/bi991209w","article-title":"The receptor binding domain of apolipoprotein E, linked to a model class A amphipathic helix, enhances internalization and degradation of LDL by fibroblasts","volume":"39","author":"Datta","year":"2000","journal-title":"Biochemistry"},{"key":"10.1016\/j.biopha.2024.116737_bib74","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S0022-2275(20)39756-X","article-title":"Structural features of synthetic peptides of apolipoprotein E that bind the LDL receptor","volume":"36","author":"Dyer","year":"1995","journal-title":"J. Lipid Res"},{"key":"10.1016\/j.biopha.2024.116737_bib75","doi-asserted-by":"crossref","first-page":"20539","DOI":"10.1016\/S0021-9258(17)32027-6","article-title":"A nonexchangeable apolipoprotein E peptide that mediates binding to the low density lipoprotein receptor","volume":"269","author":"Mims","year":"1994","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2024.116737_bib76","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/S0006-8993(97)00877-9","article-title":"Identification of a neuronal endocytic pathway activated by an apolipoprotein E (apoE) receptor binding peptide","volume":"778","author":"Wang","year":"1997","journal-title":"Brain Res."},{"key":"10.1016\/j.biopha.2024.116737_bib77","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1084\/jem.20131660","article-title":"Transferrin receptor (TfR) trafficking determines brain uptake of TfR antibody affinity variants","volume":"211","author":"Bien-Ly","year":"2014","journal-title":"J. Exp. Med"},{"key":"10.1016\/j.biopha.2024.116737_bib78","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.neuron.2013.10.061","article-title":", Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle","volume":"81","author":"Niewoehner","year":"2014","journal-title":"Neuron"},{"key":"10.1016\/j.biopha.2024.116737_bib79","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002230","article-title":"Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target","volume":"3","author":"Yu","year":"2011","journal-title":"Sci. Transl. Med."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224006218?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224006218?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T19:42:17Z","timestamp":1741030937000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332224006218"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":79,"alternative-id":["S0753332224006218"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2024.116737","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficient systemic CNS delivery of a therapeutic antisense oligonucleotide with a blood-brain barrier-penetrating ApoE-derived peptide","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2024.116737","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"116737"}}